Docstoc

Eli Lilly

Document Sample
Eli Lilly Powered By Docstoc
					Drug                  Target                               Indication
ABT-869               multiple tyrosine kinase inhibitor   Non Small Cell Lung Cancer (NSCLC)
ABT-263               Bcl-2 inhibitor                      Small Cell Lung Cancer (SCLC)
veliparib / ABT-888   PARP inhibitor                       Various cancer types
Type                       Type
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Drug                      Target                        Indication
AP23573                   mTOR                          Solid tumours
AS703026                  MEK                           Solid tumours
AS703569                  Aurora Kinases                Solid tumours
EMD1201081                Toll like receptor 9 agonist Solid tumours
EMD525797                 Integrin Inhibitor            Colorectal
EMD531444                 IL-17                         NSCLC
L778                                                    Solid
                          123 farnesyltransferase inhibitor tumours
MK0457                    Aurora Kinases                Solid tumours
MK-0646 Dalotuzumab       IGFIR                         Colorectal, breast, NSCLC
MK0683 (Vorinostat)       HDAC inhibitor                Solid tumour
MK-0731                   KSP/EG5                       Solid tumours
MK-0752                   NOTCH                         Breast cancer
MK0966                    Cyclooxygenase 2 inhibitor Solid tumous
MK-1496                   Polo-like Kinase inhibitor    Solid tumours
MK-1775                   Wee1                          Solid tumours
MK-2206                   Akt                           Solid tumours
MK2461                    C-MET inhibitor               Solid tumours
MK-4827                   PARP                          Solid Tumours Ovarian
MK-5108                   Aurora Kinases                Solid tumours
MK6592                    Aurora Kinases                Solid tumours
MK-8033                   cMET                          Solid tumours
mk-8669 (Deforolimus)     mTOR                          Breast cancer
MSC1936369B               MEK                           Solid Tumours
ridaforolimus (M-8669)    Mtor                          Sarcoma and other cancer types
SCH727965                 cdk inhibitor                 Advanced Cancer
SCH-727965 Dinaciclib     cdk inhibitor                 Cancer/Melanoma
Selectikine (EMD525873)   IL-2                          Solid Tumours
V930/932                  Her-2 CEA                     Breast Ovarian NSCLC
V934/V935                 Telomerase hTERT              Solid Tumours
VX680                     Aurora Kinases                Solid tumours
MK-4721                   anti-PSCA monoclonal          Various cancer types
MK-0822                   cathepsin K inhibitor         Various cancer types
Type                       Phase
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Agonist                    I
Small molecule inhibitor   I
Vaccine                    I
Small molecule inhibitor   I
Small molecule inhibitor   I
Monoclonal Antibody        I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   II
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   II
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Monoclonal Antibody        I
Vaccine                    I
Vaccine                    I
Small molecule inhibitor   I
Monoclonal Antibody        I
Small molecule inhibitor   II
Novartis
Drug                    Target
Afinitor (Everolimus)   mTOR
ASA404                  Vascular disrupting agent
AUY922                  HSP90
BEZ235                  Mtor and PI3K
BGJ398                  FGFR
BHQ880                  DKK1 (Dickkopf) neutralising antibody
BKM120                  PI3K
BYL719                  PI3K
EPO-906                 microtubues
HCD120 (Lucatumamub)    anti-cd40 and mediate ADCC activity
HSP990                  HSP90
INC280                  C-MET inhibitor
INC424 (INCB018424)     JAK1/JAK2 inhibitor
INCB028060              MET
LBH589 (Panobinostat)   Histone deacetylase inhibitor
LCL161                  IAP inhibitor
LDE225                  Smoothened
LEE101
LEQ506                  hedgehog
MEK162 (ARRY 162)       MEK inhibitor
PKC412 (Midostaurin)    PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEG
RAF265                  RAF VEGFR
SOM320 (Pasireotde)     VEGF IGF-1
TKI258 (Dovitinib)      FGFR, VEGFR
Tasigna? / nilotinib    multiple tyrosine kinase inhibitor
LBY135                  anti-DR5 monoclonal antibody
BGT226                  PI3K inhibitor
Indication
Neuroendocrine Tumour, Her2 positive breast cancer, Hepatocellular Carcinoma
Non small cell lung cancer 2nd line
Haemalytic tumours and solid tumours including breast
Solid tumours
Solid tumours
Multiple myeloma
Solid tumours
Solid tumours
CRC
Haemalytic tumours
Haemalytic tumours and solid tumours including breast
Solid tumours
Comfort III studies to maintain normal haemotopoesis
Solid tumours
Hodgkins lymphoma and haematolgical malignancies
Solid tumours
Solid tumours
Solid tumours
Solid tumours
Solid tumours
Acute myeolid leukemia
Metastatic melanoma
Solid tumours and Cushings disease
Solid tumours
Gastrointestinal Stromal Tumor (GIST)
Various cancer types
Various cancer types
Phase II
Phase II
Phase III
Phase III
Type                       Phase
Inhibitor
Small molecule inhibitor   III
Small molecule inhibitor   II
Small molecule inhibitor   I
Small molecule inhibitor   I
monoclonal antibody        I/II
Small molecule inhibitor   I
Small molecule inhibitor   I
microtubule stabiliser     I
monoclonal antibody
Small molecule inhibitor
Small molecule inhibitor   I
Small molecule inhibitor   III
Small molecule inhibitor   I
Inhibitor                  III
Mimetic                    I
Small molecule inhibitor   I
                           I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   III
Small molecule inhibitor   I
Small molecule inhibitor   III
Small molecule inhibitor   II
Small molecule inhibitor   III
monoclonal antibody        I
Small molecule inhibitor   I
Phase II
Phase II
Phase III
Phase III
Drug                              Target
CVX 060 (PF-04856884)             ANGIOPOIETIN-2 ANTAGONIST
CVX 241 (PF-05057459)             Ang2 VEGF
PF-03084014                       Gamma secretase inhibitor of NOTCH
PF-03446962                       ALK-1
PF-05212384 (PKI-587)             PI3K/mTOR
PF-03732010                       p-Cadherin
PF-03758309                       PAK4
PF-04217903                       Met inhibitor
PF-04554878                       FAK
PF-04605412                       Anti-alpha5beta1 integrin
PF-04691502                       PI3K/mTOR
PF-00562271                       FAK
PF-04449913                       Hedgehog inhibitor
Axitinib                          VEGF, PDGF
CP-675206 (Tremilimumab)          CTLA-4
Figitumamab                       IGFIR-1
PF-1367338 (formerly AG-14699)    PARP
PF-00299804                       EGFR subtypes
PD-0332991                        Cdk4
inotuzumab ozogamicin (CMC-544)   Cd22 inhibitor
axitinib                          VEGF
PF-00299804                       pan-HER inhibitor
bosutinib                         Abl and src-family
neratinib                         pan-HER inhibitor
PF-02341066 (crizotinib)          c-MET-ALK Inhibitor
Sutent                            Multiple TKI inhibitor
Torisel                           FKBP-Rapamycin Associated Protein
PD-0325991                        MEK inhibitor
SNX-5422                          HSP90
PF-00477736                       chk-1
CP751,851                         IGF-1
PF-337210                         VEGFR
SU014813                          Multiple TKI inhibitor
CP675,206                         CTLA4
PF-03814735                       Aurora Kinase
CP868,596                         PDGFR
PF-3512676                        toll-like receptor 9 agonist (TLR9)
PF-299                            pan-HER tyrosine kinase inhibitor
Indication
Solid tumours
Solid tumours
Solid tumours and leukeamia
Solid tumours
Solid tumours
Solid tumours
Solid tumours
Advanced cancer
Non haematologic malignancies
Solid tumours
Solid tumours
Head and neck, prostate, pancreatic
CML
Lung cancer Thyroid cancer
Genitourinary, Gastrointestinal Cancers, Melanoma, *Renal Cell Carcinoma, *Pancreatic
Gastrointestinal Cancers, Genitourinary, Ewing's Sarcoma, Small Cell Lung Cancer, Breast Cancer
Breast Cancer
NSCLC, GBM, Gastric, Head and Neck
GBM, Breast, solid tumours
Non hodgkins lymphoma
Renal Cell Carcinoma
Lung Cancer
CML
Breast Cancer
Lung Cancer
Renal Cell Carcinoma
Renal Cell Cancer
Melanoma
Haematologic Neoplasms
Neoplasms
Lung cancer
Neoplasms
Neoplasms
Prostate Cancer
Solid tumours
Solid tumours
Non Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer (NSCLC)
Type                       Phase
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Monoclonal antibody        I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Monoclonal antibody        I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   II
Monoclonal antibody        II
Monoclonal antibody        II
Small molecule inhibitor   II
Small molecule inhibitor   II
Small molecule inhibitor   II
Immunocongugate            II
Tyrosine Kinase            III
Tyrosine Kinase            III
Small molecule inhibitor   III
Small molecule inhibitor   III
Small molecule inhibitor   III
Small molecule inhibitor   III
Small molecule inhibitor   III
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I
Small molecule inhibitor   I/II
Small molecule inhibitor   I
Small molecule inhibitor   I
Monoclonal antibody        I
Small molecule inhibitor   I
Small molecule inhibitor   I
agonist                    II
Small molecule inhibitor   II
Roche
Drug                Target                                     Indication
RG3639              dual pro-apoptotic receptor agonist        cancer
RG7112              MDM2 antagonist                            solid and hematological tumors
RG7160              huMAb EGFR                                 solid tumors
RG7167              CIF/MEK inhibitor                          solid tumors
RG7256              BRAF kinase inhibitor                      BRAF-mutated malignant melanoma
RG7304              Raf/MEK dual inhibitor                     solid tumors
RG7321              PI3 kinase inhibitor                       solid tumors
RG7334              anti-PLGF                                  solid tumors
RG7347              anti-NRP1                                  solid tumors
RG7414              anti-EGFL7                                 solid tumors
RG7420              MEK inhibitor                              solid tumors
RG7421              MEK inhibitor                              solid tumors
RG7422              PI3 kinase inhibitor                       solid tumors
RG7440              AKT inhibitor                              solid tumors
RG7444              Anti-Fibroblast growth factor receptor 3   Oncology
RG7459              IAP antagonist                             oncology
RG7593              anti-CD22 monoclonal antibody              solid tumors
RG7594              anti-angiogenic                            advanced solid tumors
RG7597              anti-HER3/EGFR monoclonal antibody         solid tumors
liver cancer        anti-Glypican                              liver cancer
RG1273              HER2 dimerisation inhibitor                early breast cancer HER2+
RG1273              HER2 dimerisation inhibitor                metastatic breast cancer HER2+ 2nd line
RG3502              anti-HER2 monoclonal antibody-cytotoxic    HER2+ early breast cancer
RG3616              hedgehog pathway inhibitor                 operable basal cell carcinoma
RG3616              hedgehog pathway inhibitor                 advanced basal cell carcinoma
RG3638              MetMAb/Anti-c-Met                          solid tumors
RG7159              3rd generation anti-CD20 antibody          aggressive Non Hodgkin's lymphoma
RG7204              BRAF kinase inhibitor                      malignant melanoma 2nd / 3rd line
RG7433 navitoclax                                              solid tumors and hematologic
gastric cancer      topoisomerase I inhibitor                  gastric cancer
RG7159              3rd generation Anti-CD 20 antibody         CLL
RG7159              3rd generation anti-CD20 antibody          indolent NHL
RG7204              BRAF kinase inhibitor                      malignant melanoma 1st line
Type                  Phase
therapeutic protein   I
small molecule        I
monoclonal antibody   I
small molecule        I
small molecule        I
                      I
small molecule        I
monoclonal antibody   I
monoclonal antibody   I
monoclonal antibody   I
small molecule        I
small molecule        I
small molecule        I
small molecule        I
monoclonal antibody   I
small molecule        I
monoclonal antibody   I
monoclonal antibody   I
monoclonal antibody   I
monoclonal antibody   I
monoclonal antibody   II
monoclonal antibody   II
monoclonal antibody   II
small molecule        II
small molecule        II
monoclonal antibody   II
monoclonal antibody   II
small molecule        II
small molecule        II
small molecule        II
monoclonal antibody   III
monoclonal antibody   III
small molecule        III
Amgen
Product Name
AMG102
AMG208
AMG337
AMG386
AMG479
AMG655
AMG706
AMG780
AMG820
AMG888
AMG900
Conatumumab (AMG 655)
Denosumab
Dulanermin (rhApo2L/TRAIL)
Motesanib diphosphate
Motesanib diphosphate
Nplate® (romiplostim)
Vectibix® (panitumumab)
Vectibix® (panitumumab)
Vectibix® (panitumumab)
Target
HGF/SF
c-MET
c-MET
Angiopoietin 1 and 2
Antagonist of IGF-1 receptor
pro-apoptotic TRAIL receptor-2 agonist
anti-vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR 1-3) (oral)
Angiogenesis inhibitor
c-fms macrophase function
HER3/EGFR3
Aurora Kinases A,B,C
Death Receptor 5
RANKL
Death Receptor 4 and 5
VEGFR-1,2,3 and PDGFR and SCFR
VEGFR-1,2,3 and PDGFR and SCFR
TPO receptor
EGFR
EGFR
EGFR
Indication
Various Cancer types
Various Cancer types
Various Cancer types
Various Cancer types
Various Cancer types
Neo-adjuvant Breast cancer
Breast cancer NSCLC
Various Cancer types
Various Cancer types
Various Cancer types
Various Cancer types
Various Cancer types
bone metastases, multiple myeloma, Prostate cancer, breast cancer
Various Cancer types
First Line Breast Cancer
First Line NSCLC
NSCLC and Lymphoma
Head and Neck cancer
First and second line colorectal
Metastatic/recurrent head and neck cancer
Class                                 Phase
Small molecule inhibitor              Phase I
Small molecule inhibitor              Phase I
Small molecule inhibitor              I
Peptibody                             Phase II
Fully humanised monoclonal antibody   Phase II
Agonist                               II
Small molecule inhibitor              III
Small molecule inhibitor              I
Fully humanised monoclonal antibody   Phase I
Fully humanised monoconla antibody    Phase I
Small molecule inhibitor              Phase I
Fully humanised monoclonal antibody   Phase II
Fully humanised monoclonal antibody   Phase III
Recombinant human protein             Phase II
Small molecule inhibitor              Phase II
Small molecule inhibitor              Phase III
Peptibody                             Phase II
Fully humanised monoclonal antibody   Phase II
Fully humanised monoclonal antibody   Phase III
Fully humanised monoclonal antibody   Phase III
Product Name             Target
BMS-184476               Taxane
BMS-188797               Taxane
BMS-214662               farnesyltransferase inhibitor
BMS599626                EGFR/ Her2
BMS-641988               Anrogen Receptor agonist
BMS-690514               HER/VEGFR
BMS-754807               IGF-1R antagonist
BMS-817378               MET/VEGFR-2
BMS-863233               Cdc7 inhibitor
BMS-906024               kappa B kinase
BMS-907351 (XL184        MET, VEGFR2, and RET
BMS-908662               RAF Kinase inhibitor
Brivanib (BMS-582664)    VGFR FGFR
Elotuzumab               Anti-CS1
Epofolate (BMS-753493)   folate receptor
                         Anti-CD137
                         Anti-CD19
MDX-1105                 Anti-PDL1
MDX-1106                 Anti-PD1
                         Anti-CD70 ADC
                         Anti-CXCR4
                         Notch inhibitor
                         Adnectin Bispecific
                         VEGF R-2 Adnectin
                         ErbB/VEGF inhibitor
                         JAK2 inhibitor
                         SMO antagonist
tanespimycin / KOS-953   Hsp90 inhibitor
ipilimumab / MDX-010     anti-CTLA4 monoclonal antibody (humanized)
elotuzumab / Huluc63     anti-CS1 monoclonal antibody (humanized)
KOS-1584                 epothilone
MDX-1342                 anti-CD19 monoclonal antibody (humanized)
MDX-1411                 anti-CD70 monoclonal antibody (humanized)
MDX-1401                 anti-CD30 monoclonal antibody (humanized, non-fucosylated)
MDX-1411                 anti-CD70 monoclonal antibody (humanized)
KOS-1803                 epothilone
KOS-2464                 nuclear export inhibitors (NEI)
Indication                              Class                      Phase
solid tumours                           Taxoid                     I
solid tumours                           Taxoid                     I
Solid tumours                           Small molecule inhibitor   I
Solid tumours                                                      I
Solid tumours                           Small molecule inhibitor   I
solid tumours                           Small molecule inhibitor   I
Oncology                                                           I/II
Solid tumours                           Small molecule inhibitor   I
Oncology                                Haematologic cancer        I/II
solid tumours                           Small molecule inhibitor   I
Solid tumours                           Small molecule inhibitor   I
Oncology                                                           I/II
Solid tumours                           Small molecule inhibitor   I
Oncology                                                           I/II
Solid tumours                           Small molecule inhibitor   I
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                Small molecule inhibitor   I/II
Oncology                                                           I/II
Oncology                                                           I/II
Oncology                                Small molecule inhibitor   I/II
Oncology                                Small molecule inhibitor   I/II
Oncology                                antagonist                 I/II
Breast cancer                           Small molecule inhibitor   II
Melanoma Brain Metastases               Monoclonal antibody        II
Multiple Myeloma                        Monoclonal antibody        II
Non Small Cell Lung Cancer (NSCLC)                                 II
Chronic Lymphocytic Leukemia (CLL)      Monoclonal antibody        I
Clear cell Renal cell carcinoma (RCC)   Monoclonal antibody        I
Hodgkin's Lymphoma                      Monoclonal antibody        I
Lymphoma                                Monoclonal antibody        I
Various cancer types                                               Preclinical
Various cancer types                    Small molecule inhibitor   Preclinical
Eli Lilly
Product Name
arzoxifene (LY353381)
Enzastaurin
IC83/LY2603618
LY2090314
LY2157299
LY2181308
LY2523355
LY2584702
LY2603618
LY2606368
LY2624587
LY2780301
LY2801653
LY2874455
LY2875358
LY293111 Etalocib
LY2940680
LY3012217
LY573636
LY900003
Panitumumab
Pemetrexed
Ramucirumab
Tasisulam
IMC-A12
IMC-3G3
IMC-18F1
AME133v
Survivin ASO
SGX523
Target
Eostrogen receptor
PKC
CHK-1
glycogen synthase kinase 3 inhibitor
TGF-Beta
Survivin
Eg5
p70S6K
CHK2
CHK1
?
AKT
c-MET
?
c-MET
BLT1
?
?
Novel acyl sulfonamide
PKC Alpha
EGFR
DNA Synthesis
VEGF
acyl-sulfonamide compound
insulin-like growth factor-1 receptor (IGF-1R) inhibitor (humanized monoclonal antibody)
anti-platelet derived growth factor receptor alpha (PDGFR(alpha)) monoclonal antibody (humanized)
anti-VEGFR-1 monoclonal antibody (humanized)
anti-CD20 monoclonal antibody
antisense oligonucleotide
MET kinase inhibitor
Indication                                                         Class
Breast Cancer Osteoporosis                                         selective estrogen receptor modulator
non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate   synthetic bisindolemaleimide
Cancer                                                             Small molecule inhibitor
acute myelogenous leukemia                                         Small molecule inhibitor
Glioma Hepatocellular Carcinoma                                    Small molecule inhibitor
metastatic malignancies                                            Antisense oligonuceotide
Ovarian, NSCLC, Leukemia prostate                                  Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
NSCLC, Pancreatic                                                  Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Pancreatic, Solid tumours, NSCLC                                   Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Cancer                                                             Small molecule inhibitor
Melanoma                                                           ?
NSCLC                                                              Antisense oligonuceotide
Colon Cancer                                                       Monoclonal Antibody
NSCLC Mesothelioma
Breast cancer                                                      Monoclonal Antibody
Solid tumours                                                      Apoptosis inducer
Various cancer types                                               Monoclonal Antibody
Breast cancer                                                      Monoclonal Antibody
Breast cancer                                                      Monoclonal Antibody
Non-Hodgkin's Lymphoma (NHL)                                       Monoclonal Antibody
Various cancer types                                               oligonucleotide
Various cancer types                                               Small molecule inhibitor
Phase
III
II
II
II
II
II
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II-III
III
III
I
II
I
I
I
I
I
Product Name           Target                  Indication             Class                      Phase
CEP-18770              Proteasome inhibitor    Multiple Myeloma       Small molecule inhibitor   II
CEP-9722               PARP                    Solid Tumours, NSCLC   Small molecule inhibitor   II
CEP-11981              VEGF-R TIE2 inhibitor   Solid Tumours          Small molecule inhibitor   I
CEP-37440              ALK/FAK inhibitor       NSCLC and Prostate     Small molecule inhibitor   pre-clinical
CEP-32496              BRAF inhibitor          Melanoma               Small molecule inhibitor   pre-clinical
CEP-37250              glycolipids             CRC                    Small molecule inhibitor   pre-clinical
CEP-701                FLT3                    Multiple Myeloma       Small molecule inhibitor   I
SDX-101 Lestaurtinib   R-etodolac              Multiple Myeloma       NSAID                      I
SDX-105                Nitrogen mustard        CLL                    Nitrogen Mustard           I
Product Name                   Target
Alpharadin                     alpha radiation
CA9-ADC                        Carboanhydrase 9
CDK-Inhibitor                  CDK
L19-SIP                        fibronectin
L19-TNFalpha                   TNF-alpha
MEK-Inhibitor                  MEK-Inhibitor
PI3K-Inhibitor                 PI3K-Inhibitor
Regorafenib                    VEGFR2-TIE2
Sagopilone                     epothilone
BAY86-9766                     MEK-Inhibitor
BAY80-6946                     PI3K-Inhibitor
BAY87-2243                     carbonic anhydrase 9 and VEGF
BAY79-4620                     CA IX
BAY1000394                     CDK
BAY86-5284                     radiolabelled synthetic peptide
SH U04722                      IRF-1
PTK787/ZK 222584 (vatalanib)   VEGF
Indication                                   Class                      Phase
Bone Metastases in Breast, Prostate Cancer   radiation                  II
Cancer                                       fusion antibody            I
Cancer                                       Small molecule inhibitor   I
Brain Metastases, Lung Cancer                fusion antibody            II
Colorectal Cancer                            fusion antibody            I
Cancer                                       Small molecule inhibitor   I
Cancer                                       Small molecule inhibitor   I
Colorectal Cancer (CRC) GIST                 Small molecule inhibitor   III
Cancer                                       epothilone                 II
Solid tumours                                Small molecule inhibitor   I
Solid tumours                                Small molecule inhibitor   I
Solid tumours                                Small molecule inhibitor   I
Solid tumours                                antibody conjugate         I
Solid tumours                                Small molecule inhibitor   I
Solid tumours                                radiolabelled synthetic    I
Solid tumours                                Small molecule inhibitor   I
Solid tumours                                Small molecule inhibitor   I
Wilex
Drug                               Target                        Indication
Rencarex WX-G250                   G250 antigen / anhydrase IX   Renal Cell cancer
Mesupron                           UPA                           Solid tumours
WX-554                             MEK                           Solid tumours
WX-037                             PI3K                          Solid tumours
WX-UK1                             UPa                           Solid tumours
WX-671                             Serine protease inhibitor     breast cancer
Anavex Life Sciences Corporation
Drug                               Target                        Indication
Anavex 1079                        Sigma1 Sigma 2                Melanoma Prostate Pancreatic
Anavex 1007                        Sigma1 Sigma 2                Prostate
Anavex 1519                        Sigma1 Sigma 2                Prostate
Anavex 1066                        Sigma1 Sigma 2                Prostate Pancreas
Basilea Pharmaceutica AG
Drug                               Target                        Indication
BAL101553                          microtubule inhibitor         Solid tumours
Debiopharm Group
Drug                               Target                         Indication
Debio 0507                         Platinum micellar nanoparticlesSolid tumours
Debio 0932                         HSP90                          Solid tumours
Debio 0719                         LPA receptor agonists          Oncology
Debio 0928                         Raf1-Rb inhibitor              Oncology
Debio 0617                         undisclosed target             Oncology
Debio 0826                         undisclosed target             Oncology
Debio 0929                         undisclosed target             Oncology
Gene Signal
Drug                               Target                        Indication
GS-497c                                                          Lung cancer
GS-168                                                           Kidney Cancet
GS-326                                                           Pancreatic Cancer
GS-101                                                           Genital cancer
GS-156                                                           Solid tumours
Med Discovery S.A.
Drug                               Target                        Indication
MDKP67b                            Kallikrein 2                  Prostate
MDP01                              EGFR                          Solid tumours
Oncalis AG
Drug                               Target                        Indication
ONC-201                            PI3K                          Solid tumours
Pevion Biotech Ltd.
Drug                               Target                        Indication
PEV-6                              Her2                          breast cancer
Telormedix SA
Drug                               Target                        Indication
TMX-101                                                          Bladder cancer
TMX-202                            TLR7                          Solid tumours
Trin Pharma GmbH
Drug                               Target                        Indication
TRIN-2755                          Triazene analogue             Solid tumours
Class                               Phase
Monoclonal Antibody                 III
Small molecule inhibitor            II
Small molecule inhibitor            I
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            I
Small molecule inhibitor            II

Class                               Phase
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical

Class                               Phase
Small molecule inhibitor            pre-clinical

Class                               Phase
Small molecule inhibitor            I
Small molecule inhibitor            I
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical
Small molecule inhibitor            pre-clinical

Class                               Phase
                                    pre-clinical
                                    pre-clinical
                                    pre-clinical
                                    pre-clinical
Monoclonal Antibody                 pre-clinical

Class                               Phase
Small molecule inhibitor            pre-clinical
Peptabody                           pre-clinical

Class                               Phase
Small molecule inhibitor            pre-clinical

Class                               Phase
Antibody fused with viral vaccine   I

Class                               Phase
Small molecule inhibitor            I/II
Small molecule inhibitor            pre-clinical

Class                               Phase
Small molecule inhibitor            I
Biolife Science Forschungs- Und Entwicklungsges Mb
Product Name          Target Indication              Class     Phase
HerVac                HER2 Breast cancer             Vaccine   pre-clinical
MimoVac               HER2 Breast cancer Melanoma    Vaccine   pre-clinical
CureVac
Drug                     Target
CV9103                   Stimulate T cell response
CV9201                   Stimulate T cell response
Curacyte
Drug                     Target
Hemoximer                Nitric oxide scavenger
Glycotope
Drug                     Target
GT-MAB 2.5-GEX           MUC1
GT-MAB 5.2-GEX           ?
GT-MAB 3.2-GEX           ?
GT-MAB 7.3-GEX           ?
GT-GP 2.4-GEX            ?
Ganymed
Drug                     Target
Claudiximab (iMAB362)    GC182
GT512iMABs               GT512
GT468iMABs               GT468
IMAB362                  ?
Fresenius Biotech GmbH
Drug                     Target
Removab (Catumaxumab)    EpCam
Ertumaxomab              Her-2
FBT-A05                  CD20
Celonic Gmbh
Drug                     Target
Atrosab                  TNF-1
Oncarex
CellGenix
Drug                     Target
IdioVax                  B cell receptor
Cellact Pharma
Drug                     Target
CAP7.1                   topioisomerase
CAP1.1                   TIRC 7
CAP1.2                   TIRC 7
CAP2.1                   CEACAM1
CAP2.2                   CEACAM1
CAP3.1                   HLA Class II
CAP3.2                   HLA Class II
Apogenix
Drug                     Target
APG-101                  CD95
Various                  IL-4 blocker
Antisense Pharma
Drug                     Target
trabedersen (AP 12009    TGF-Beta 2
AP 11014                 TGF-Beta 1
AP 15012                 TGF-Beta
Affirmed Therapeutics
Drug                     Target
AFM-13                   CD30xCD16
AFM-11                   CD19xCD3
AFM-12                   CD19xCD12
AFM-20                   EpCam
AFM-21                             EGFR-1
4SC
Drug                               Target
4SC-201 (Resminostat)              Pan HDAC inhibitor
4SC-203                            FLT3, FLT3 mutants and VEGF- receptors
4SC-205                            Eg5 kinesin spindle protein inhibitor
4SC-202                            Class I HDAC inhibitor
4SC-207                            anti-mitotic compound
Agennix
Drug                               Target
Talactoferrin                      Lactoferrin
RGB-286638                         cdk inhibitor
Satraplatin                        Platinum based chemotherapy
Heidelberg Pharma
Drug                               Target
Antibody Drug conjugates           Multiple
fosfluridine                       ?
Enhanced Pro-Drug of Clofarabine   ?
Immatics Biotechnologies GmbH
Drug                               Target
IMA901
IMA910
IMA950
IMA9XX
Intermed Discovery
Drug                               Target
IMD-026259                         ?
IMD-026260                         ?
Jerini AG
Drug                               Target
JSM6427                            alpha5beta1 integrin
Me Medical Enzymes AG
Drug                               Target
GlutaDON                           L-glutamine
Medigene AG
Drug                               Target
G207                               Geneticall enginerred HSV-1
NV-1020                            HSV-1
EndoTag-1                          antitumour and antiangiogenic
Micromet, Inc. (Cancervax Corporation)
Drug                               Target
Blinatumomab (MT103)               CD19
MT110                              EpCam
MT111                              carcinoembryonic antigen (CEA
Canvaxin
MT228                              GD2
Mologen Holding AG
Drug                               Target
MGN-1703                           TLR9
MGN-17xx                           ?
MGN-1601                           ?
Morphosys AG
Drug                               Target
MOR208                             CD19
MOR202                             CD38
MOR205                             ?
MOR206                    ?
Multimmune GmbH
Drug                      Target
EnkaStim-ex vivo          HSP70
EnkaStim-in vivo          HSP70
mi-TUMEX                  HSP70
mi-APO                    HSP70
Noxxon Pharma AG
Drug                      Target
NOX-A12                   SDF-1 (CXCL12)
NOX-S91                   S1P (sphingosine-1-phosphate)
Oncoscience AG
Drug                      Target
Nimotuzumab
OSAG101                   EGFR
Pieris Proteolab AG
Drug                      Target
PRS-050                   VEGF
PRS-110                   C-MET
Priaxon AG
Drug                      Target
mdm2/p53 inhibitor        p53
mdmx/p53 inhibitor        p53
Provecs Medical GmbH
Drug                      Target
Immunalon                 Inflammatory stimulator of cd137, il-2, il-12
Resprotect GmbH
Drug                      Target
RP101                     HSP27
RP656                     HSP27
RP701                     HSP27
RP885                     HSP27
Symbiotec, GmbH
Drug                      Target
Oncohist                  HDAC
Trion Pharma GmbH
Drug                      Target
Rexomun                   Her-2 neu
Lymphomun                 CD20
Ektomun                   ?
Vakzine Project Manager
Drug                      Target
VPM4001                   IL-2 IFN-y
Indication                                                         Class
Hormone refractory prostate cancer                                 RNA active molecule
NSCLC                                                              RNA active molecule

Indication                                                         Class
Metastatic melanoma                                                modified hemoglobin

Indication                                                         Class
Gastric, Lung, Breast, Pancreatic                                  Antibody
Colorectal, Head and Neck                                          Antibody
                                                                   Antibody
                                                                   Antibody
                                                                   Glycoprotein

Indication                                                         Class
gastric, pancreatic, NSCLC                                         Monoclonal Antibody
Gastric NSCLC                                                      Monoclonal Antibody
Breast Ovarian, NSCLC                                              Monoclonal Antibody
Solid tumours                                                      Monoclonal Antibody

Indication                                                         Class
malignant ascites                                                  Monoclonal antibody
breast and gastric cancer                                          Monoclonal antibody
Lymphomas and leukemia                                             Monoclonal antibody

Indication                                                         Class
Acute inflammatory disease                                         Antibody
Head and Neck cancer                                               L-aminooxidase

Indication                                                         Class
Non-Hodgkin´s B-cell lymphomas                                     Vaccine

Indication                                                         Class
cancer                                                             Small molecule
Inflammation and oncology disorders                                Antibody
Inflammation and oncology disorders                                Small molecule
collitis and arthritis                                             recomminant protein
inflammatory disorders                                             Antibody
inflammatory disorders                                             recomminant protein
inflammatory disorders                                             Antibody

Indication                                                         Class
Glioblastoma                                                       Antibody
Cancer                                                             Antibody

Indication                                                         Class
anaplastic astrocytoma, Malignant melanoma, prostatic colorectal   Antisense
Lung prostate cancer                                               Antisense
Neoplasms                                                          Antisense

Indication                                                         Class
Hodgkin lymphoma                                                   Antibody
Non-hodgkin lymphoma                                               Antibody
Hodgkin lymphoma                                                   Antibody
Solid tumours                                                      Antibody
Solid tumours                              Antibody

Indication                                 Class
Colon, HCC, hodgkins lymphoma              Small molecule inhibitor
Solid tumours                              Small molecule inhibitor
Solid tumours                              Small molecule inhibitor
Cancer                                     Small molecule inhibitor
Cancer                                     Small molecule inhibitor

Indication                                 Class
NSCLC                                      recomminant protein
Solid tumours                              Small molecule inhibitor
Prostate                                   Platinum chemotherapy

Indication                                 Class
Solid tumours                              Monoclonal Antibody
Actinic keratosis                          ?
refractory acute lymphoblastic leukaemia   ?

Indication                                 Class
Renal                                      tumour associated peptides
Colorectal                                 tumour associated peptides
Glioblastoma                               tumour associated peptides
Various                                    tumour associated peptides

Indication                                 Class
CNS                                        ?
Solid tumours                              ?

Indication                                 Class
Solid tumours                              Small molecule inhibitor

Indication                                 Class
Colorectal, renal, NSCLC                   Antagonist

Indication                                 Class
Glioma                                     Vaccine
Colorectal Liver                           Vaccine
TNBC                                       Paclitaxal linked to lisosomes

Indication                                 Class
ALL                                        Monoclonal Antibody
Solid tumours                              Monoclonal Antibody
GIST                                       Monoclonal Antibody
Melanoma                                   Monoclonal Antibody
Melanoma                                   Monoclonal Antibody

Indication                                 Class
Colorectal cancer                          TLR Agonist
Prostate                                   ?
Solid tumours                              ?

Indication                                 Class
CLL                                        Monoclonal Antibody
Multiple Myeloma                           Monoclonal Antibody
cancer                                     Monoclonal Antibody
cancer                                     Monoclonal Antibody

Indication                                 Class
Lung colorectal                            NK Cell activator
Solid tumours                              Cancer vaccine
Solid tumours                              Monoclonal Antibody
Solid tumours                              Small molecule inhibitor

Indication                                 Class
Haematological tunours and solid tumours   oligo linked to PEG
Solid tumours                              Small molecule inhibitor

Indication                                 Class
Pancreatic cancer and glioma               Monoclonal Antibody
Solid tumours                              Monoclonal antibody

Indication                                 Class
Solid tumours                              PEGylated Anticalin
Solid tumours                              Small molecule inhibitor

Indication                                 Class
cancer                                     Small molecule inhibitor
cancer                                     Small molecule inhibitor

Indication                                 Class
Solid tumours                              Andeoviral vector

Indication                                 Class
Pancreatic cancer                          Small molecule inhibitor
Cancer                                     Small molecule inhibitor
Cancer                                     Small molecule inhibitor
Cancer                                     Small molecule inhibitor

Indication                                 Class
AML, breast                                Small molecule inhibitor

Indication                                 Class
Breast                                     Monoclonal Antibody
B cell lymphoma                            Small molecule inhibitor
Melanoma                                   Small molecule inhibitor

Indication                                 Class
Prostate                                   Vaccine
Phase
IIA
IIA

Phase
III

Phase
I
I
preclinical
preclinical
preclinical

Phase
II
pre-clinical
pre-clinical
II

Phase
Phase II
Phase II
Phase I

Phase
preclinical
preclinical

Phase
II

Phase        Comments
pre-clinical
pre-clinical
pre-clinical
pre-clinical suppress severity of T helper (Th) cell-mediated colitis and collagen induced arthritis
pre-clinical
pre-clinical
pre-clinical

Phase
II
preclinical

Phase
III
preclinical
preclinical

Phase
I
Preclinical
Preclinical
Preclinical
Preclinical

Phase
II
I
I
pre-clinical
pre-clinical

Phase
III
I
II

Phase
?
II
II

Phase
III
II
I
preclinical

Phase
preclinical
preclinical

Phase
preclinical

Phase
I/II

Phase
I
II
II

Phase
II
I
I
II
preclinical

Phase
II
II
I

Phase
I
I
Preclinical
preclinical

Phase
I
preclinical
preclinical
preclinical

Phase
preclinical
preclinical

Phase
I
I

Phase
I
preclinical

Phase
preclinical
preclinical

Phase
I

Phase
II/III
preclinical
preclinical
preclinical

Phase
I

Phase
II
I
I

Phase
I/II
Drug                         Target
BIBF 1120 (Vargatef TM **)   Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR
BIBF 1120                    Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR
Afatinib                     Dual irreversible EGFR/HER2 inhibitor
Afatinib                     Dual irreversible EGFR/HER2 inhibitor
Volasertib                   PLK-1 antagonist
New compound                 Mitotic checkpoint inhibitor
Indication       Class                            Phase
NSCLC            Angiogenesis inhibition          Phase III
Ovarian cancer   Angiogenesis inhibition          Phase III
NSCLC            Signal transduction inhibition   Phase III
Breast cancer    Signal transduction inhibition   Phase III
Solid Tumours    Cell-cycle kinase inhibition     Phase II
Solid Tumours    Cell-cycle kinase inhibition     Phase I
Drug                    Target                                               Indication
Aflibercept             VEGF1 VEGF2                                          NSCLC
Alvocidib               CDKs                                                 CLL
AVE1642                 IGF                                                  Multiple myeloma
AVE8062                 vascular disrupting agent                            Sarcoma
AVE9633                 anti-CD33 monoclonal antibody (maytansin-loaded)     Acute Myelogenous Leukemia (AML)
BSI-201                 PARP
Cabazitaxel (XRP6258)   microtubule stabilisers                              prostate
Larotaxel (XRP9881)     microtubule stabilisers                              pancreatic
Ombrabulin (AVE8062)    microvessels                                         Soft tissue Sarcoma
REGN421                 DLL4                                                 Solid tumours
SAR103168               multiple TKI inhibitor                               AML
SAR132885               centromere-associated protein E (CENP-E) inhibitor   Various cancer types
SAR307746               PI3K mTOR                                            Solid tumours
SAR3419                 CD19                                                 Lymphoma
SAR566658               anti-DS6                                             Solid tumours
SAR567530               Hsp90 inhibitor                                      Various cancer types
SAR650984               CD38                                                 Haematologic malignancy
SSR97225                Tubulin                                              Solid tumours
XL147                   PI3K                                                 NSCLC
XL765                   PI3K mTOR                                            GBM NSCLC
SSR244738               antitumoral agent                                    Various cancer types
Class                       Phase
fusion protein              III
Small molecule inhibitors   I
Monoclonal Antibody         I
Small molecule inhibitor    III
Monoclonal antibody         I
Small molecule inhibitors
taxoid compounds            III
taxoid compounds            III
                            III
Monoclonal antibody         I
Small molecule inhibitor    I
Small molecule inhibitor    Preclinical
Small molecule inhibitor    I
Monoclonal antibody         I
Monoclonal antibody         I
Small molecule Inhibitor    Preclinical
Monoclonal Antibody         I
Tubulin binding agent
Small molecule inhibitor    I
Small molecule inhibitor    I
antitumoral agent           I
Drug                                           Target
AZD1152                                        Aurora Kinase
AZD1480                                        JAK2 inhibitor
AZD2014                                        TOR kinase inhibitor
AZD2461                                        PARP inhibitor
AZD3514                                        androgen receptor
AZD4547                                        FGFR tyrosine kinase
AZD5363                                        AKT inhibitor
AZD7762                                        CHK1 kinase inhibitor
AZD8055                                        TOR kinase inhibitor
AZD8330# (ARRY 424704)                         MEK inhibitor
AZD8931                                        ErbB kinase
CAT-8015                                       anti-CD22 recombinant immunotoxin
MEDI-3617                                      anti-ANG-2
MEDI-551                                       anti-CD19
MEDI-565                                       anti-CEA BiTE
MEDI-573#                                      anti-IGF
MEDI-575# mAb II                               anti-PDGFR-alpha
Olaparib                                       PARP
Recentin VEGFR tyrosine kinase                 VEGFR
Selumetinib (AZD6244) (ARRY-142886)            MEK
Selumetinib (AZD6244) (ARRY-142886) /MK2206#   MEK/AKT inhibitor
AZD4769                                        EGFR tyrosine kinase inhibitor
AZD4877                                        cell cycle inhibitor
AZD0530                                        SRC kinase inhibitor
MEDI-561                                       Hsp90 inhibitor
vandetanib                                     VEGF2 and EGFR tyrosine kinase inhibitor
zibotentan / ZD4054                            endothelin A receptor antagonist
Faslodex? / fulvestrant                        oestrogen receptor antagonist
Indication                               Class                 Phase
haematological malignancies              Small molecule        II
myeloproliferative disease Solid tumours Small molecule        I
Solid tumours                            Small molecule        I
solid tumours                            Small molecule        I
Prostate Cancer                          Small molecule        I
Solid tumours                            Small molecule        I
solid tumours                            Small molecule        I
Solid tumours                            Small molecule        I
range of tumours                         Small molecule        I
solid tumours                            Small molecule        I
Breast solid tumours                     Small molecule        II
haematological malignancies              immunotoxin           I
solid tumours                            Monoclonal Antibody   I
haematological malignancies              Monoclonal Antibody   I
Solid tumours                            Small molecule        I
Solid tumours                            Monoclonal Antibody   I
solid tumours                            Monoclonal Antibody   II
Ovarian                                  Small molecule        II
NSCLC                                    Small molecule        II
Solid tumours                            Small molecule        II
solid tumours                            Small molecule        I
Various cancer types                     Small molecule        I
Various cancer types                     Small molecule        I
Various cancer types                     Small molecule        II
Various cancer types                     Small molecule        II
Medullary Thyroid cancer (MTC)           Small molecule        II
                                         a
Hormone refractory Prostate cancer (HRPC) ntagonist            III
1st line metastatic Breast cancer        antagonist            III
GSK                                   Target
alkeran                               alkylating agent
amrubicin                             alkylating agent
Abraxane? / nab?-paclitaxel           microtubule inhibitor
Revlimid? / lenalidomide              immune system modulator
Thalidomide Pharmion? / thalidomide   immune system modulator
Vidaza? / azacitidine                 antimetabolite (cytidine analog)
nab?-docetaxel / ABI-008              microtubule inhibitor
pomalidomide / CC-4047                immune system modulator
amrubicin (+ cisplatin)               alkylating agent
pomalidomide / CC-4047                immune system modulator
ACE-011                               activin inhibitor
nab?-rapamycin / ABI-009              mTOR inhibitor
Vidaza? / azacitidine                 antimetabolite (cytidine analog)
Vidaza? / azacitidine                 antimetabolite (cytidine analog) (oral)
Abraxane? / nab?-paclitaxel           microtubule inhibitor
nab?-17AAG / ABI-010                  Hsp90 inhibitor
nab?-5404 / ABI-011                   topoisomerase 1 inhibitor
Indication                                               Class
Multiple Myeloma                                         III
Small Cell Lung Cancer (SCLC)                            III
1st line metastatic Melanoma                             III
Multiple Myeloma                                         III
Multiple Myeloma                                         III
Myelodysplastic Syndrome (MDS)                           III
Hormone refractory Prostate cancer (HRPC)                II
Multiple Myeloma                                         II
Small Cell Lung Cancer (SCLC)                            II
Various cancer types                                     II
Cancer related bone loss                                 I
Various cancer types                                     I
Acute Myelogenous Leukemia (AML)                         I
Myelodysplastic Syndrome (MDS)                           I
1st line metastatic Non Small Cell Lung Cancer (NSCLC)   Discontinued
Various cancer types                                     Preclinical
Various cancer types                                     Preclinical
GSK                      Target
                 2401502 Domain antibody targeted multi-component vaccine
iboctadekin† (+ Doxil)   IL18 immunomodulator (+ topoisomerase II inhibitor)
Arzerra (ofatumumab)† Anti-CD20 human monoclonal antibody
                 2110183 AKT
                 2118436 BRaf
                 2126458 Pi3 kinase inhibitor
                 2141795 AKT protein kinase inhibitor
                  184072 SIRT1 activator
                 1120212 Mitogen-activated protein kinase inhibitor (MEK1/2)
                 2285921 Thrombopoietin receptor agonist
foretinib (1363089)      Mesenchymal-epithelial transition factor (C-met)
Revolade/Promacta        Thrombopoietin receptor agonist
Tyverb/Tykerb            Her2 and EGFR dual kinase inhibitor
Votrient (pazopanib)     multi-kinase angiogenesis inhibitor
Votrient (pazopanib)     multi-kinase angiogenesis inhibitor
Votrient (pazopanib)     multi-kinase angiogenesis inhibitor
Revolade/Promacta        thrombopoietin receptor agonist
Tyverb/Tykerb            Her2 and EGFR dual kinase inhibitor
Tyverb/Tykerb            Her2 and EGFR dual kinase inhibitor
Tyverb/Tykerb            Her2 and EGFR dual kinase inhibitor
Votrient (pazopanib)     multi-kinase angiogenesis inhibitor
BRF113683                BRAF inhibitor
                         topoisomerase inhibitor
Hycamtin? / topotecan hydrochloride
XL880                    c-Met kinase inhibitor
                  690693 AKT inhibitor
                  923295 centromere-associated protein E (CENP-E) inhibitor
                  461364 polo-like kinase 1 (PLK1) inhibitor
Indication                                                       Class
Malignant melanoma                                               Fully humanised monoclonal antibody
Ovarian cancer
First line chronic lymphocytic leukaemia and relpased patients   Monoclonal antibody
Various Cancer types                                             Small molecule inhibitor
Various Cancer types                                             Small molecule inhibitor
Various Cancer types                                             Small molecule inhibitor
Various Cancer types                                             Small molecule inhibitor
haematologic cancers                                             activator
Various Cancer types                                             Small molecule inhibitor
thrombocytopaenia                                                agonist
papillary renal cell carcinoma and other cancers                 Small molecule inhibitor
oncology-related thrombocytopaenia                               agonist
head & neck squamous cell carcinoma (unresectable disease)       Small molecule inhibitor
breast cancer, adjuvant therapy                                  Small molecule inhibitor
non-small cell lung cancer, first line & adjuvant therapy        Small molecule inhibitor
ovarian cancer, maintenance therapy                              Small molecule inhibitor
chronic liver disease induced thrombocytopaenia                  agonist
breast cancer, adjuvant therapy                                  Small molecule inhibitor
gastric cancer                                                   Small molecule inhibitor
head & neck squamous cell carcinoma (resectable disease)         Small molecule inhibitor
sarcoma                                                          Small molecule inhibitor
Advanced or metastatic Melanoma                                  Small molecule inhibitor
1st line metastatic Ovarian cancer                               Small molecule inhibitor
Gastric cancer                                                   Small molecule inhibitor
Various cancer types                                             Small molecule inhibitor
Various cancer types                                             Small molecule inhibitor
Various cancer types                                             Small molecule inhibitor
Phase
Phase I
Phase I
Phase III
Phase I
Phase I
Phase I
Phase I
Phase III
Phase II
Phase II
Phase II
Phase II
Phase II
Phase II
Phase II
Phase III
Phase III
Phase III
Phase III
Phase III
Phase III
III
III
II
I
I
I

				
DOCUMENT INFO